Japan was once Asia’s defining technology power, setting a template for economic development while building global strength in electronics, robotics, precision manufacturing, and biomedical research. In neuroscience, it still has deep infrastructure, from national brain research programs and humanoid robotics to Shinya Yamanaka’s Nobel Prize-winning iPSC work. Yet today, Japan is rarely central in neurotechnology conversations, where regional attention has increasingly shifted toward China.
That makes Japan’s neurotech ecosystem easy to underread. Long-term public programs have kept brain science, cybernetic avatars, neural interfaces, and neuroethics moving forward, while a smaller commercial layer is beginning to form around companies such as Araya, Ivec, Ruten, and LIFESCAPES. The central challenge for Japan is to now turn their historically rich research body into globally competitive neurotechnology companies, especially as funding, regulatory pathways, and international commercialization remain fragmented.
Japan’s neurotechnology effort is anchored by two large public programs that shape much of the country’s funding and talent environment.
Brain/MINDS 2.0 is Japan’s national brain research program. Launched in March 2024 as the successor to the original Brain/MINDS program, it approved 97 priority subprojects across higher human brain functions, neurological and psychiatric disease, digital brain models, and novel therapeutic approaches. The program is funded and administered by the Japan Agency for Medical Research and Development (AMED), with the RIKEN Center for Brain Science as its core organization and Keio University and the University of Tokyo as principal partners.
Ryosuke Takahashi, the program supervisor, frames Brain/MINDS 2.0 around the integration of experimental neuroscience, data science, and clinical translation. In the program’s official greeting, he described the newly established “digital brain” theme as an effort to reconstruct brain functions in digital space using large-scale data from animals and humans, with the broader aim of advancing what he called the “fusion of wet and dry brain sciences.”
The second major initiative is the Moonshot Research and Development Program, launched in 2019 by the Cabinet Office and the Japan Science and Technology Agency (JST). Rather than funding a single research field, Moonshot sets ten long-range goals and supports high-risk projects aimed at difficult societal challenges by 2050.
.jpg)
Japan’s neurotechnology work sits most clearly inside Moonshot Goal 1, which targets a society “free from limitations of body, brain, space, and time.” The goal funds research toward Cybernetic Avatars, including teleoperated robots and BCI-controlled agents that could allow people, including older adults and people with disabilities, to participate in work and social life without physical constraints.
Osaka University, through Hiroshi Ishiguro’s lab, is one of the country’s main centers for humanoid and avatar research. Ryota Kanai’s Internet of Brains project, discussed in the next section, also sits within this Moonshot structure.
Together the two programs place neural interfaces inside a broad social agenda tied to aging, demographic decline, and future participation in work and society. Brain/MINDS 2.0 provides much of the basic neuroscience and data infrastructure, while Moonshot carries more of the translational work around avatars, brain-machine interfaces, and social implementation.
One of the key neurotechnology programs inside Moonshot Goal 1 is the Kanai Project, also known as the Internet of Brains (IoB). The project is led by Ryota Kanai, who is also CEO of Araya Inc., the Tokyo-based AI and neurotechnology company that sits near the center of Japan’s BCI activity. The Advanced Telecommunications Research Institute International (ATR) serves as the project’s representative organization.
IoB is pursuing several technical tracks in parallel, including contactless BCIs using environmental sensors, non-invasive BCIs based on scalp recordings, and minimally invasive approaches using intravascular electrodes. Its longer-term objective is to connect the brain to digital networks, allowing people to control Cybernetic Avatars in cyber-physical spaces and communicate more directly with other humans and AI systems.
.webp)
In September 2025, IoB announced a joint research partnership with Dubai Future Labs, positioning Dubai as a “living lab” for testing neurotechnology acceptance across cultural contexts. The project also co-hosted the IoB-S International Symposium “Neurolaw in Action” at Keio University in November of the same year.
Japan’s commercial neurotechnology layer remains relatively small. Industry databases such as Tracxn list just 38 neurology startups in Japan, with only about a third of those having reached Series A or later.
Araya Inc. is one of the leading firms and a clear examples of how Japan’s commercial layer overlaps with its public research agenda. The company operates across neurotechnology, applied AI, and industrial solutions and is part of Japan’s J-Startup program. Its commercial AI inspection lines help fund longer-horizon research efforts, including IoB. In March 2026, Araya launched JapanEEG, an open EEG and EMG dataset for non-invasive speech BCI research, and signed a memorandum of understanding with Australia-based FluentBCI to develop bilingual Japanese-English speech decoding.
Ivec Inc. is one of Japan’s most closely watched new neurotechnology ventures. Established in October 2025 as a University of Osaka spinout, the company is developing an intravascular BCI for amyotrophic lateral sclerosis (ALS) patients. Its approach avoids craniotomy by using cortical veins between the sensory and motor areas to measure and decode intracranial EEG. The company’s founders emerged directly from Moonshot Goal 1 and IoB, with clinical research targeted for 2028.
.jpg)
Ruten Inc., founded in July 2023, is developing an implantable BCI system to restore swallowing function after stroke. In March 2026, the company raised $2 million from Coral Capital. Ruten is also collaborating with the University of Southern California and the NIH on a peripheral nerve stimulation project for post-stroke dysphagia, and has received funding from Japan’s Defense Equipment Agency for motor and cognitive decoding research.
LIFESCAPES Inc., a Keio University spinout led by Junichi Ushiba, is developing an EEG and exoskeleton system for stroke rehabilitation. The company has secured investment from Shionogi, Beyond Next Ventures, and JGC Mirai Innovation Fund. Its hand-type rehabilitation device received cumulative orders for 20 units within two months of its mid-2024 release, indicating early commercial demand.
Japan’s broader startup ecosystem expanded significantly through 2025, particularly across deep tech and AI. For early-stage research, public capital remains the most consistent source of support. The government’s Startup Development Five-Year Plan targets ¥10 trillion, or approximately $63 billion, in startup investment and looks to produce 100 unicorns by fiscal year 2027. The plan is supported by the New Energy and Industrial Technology Development Organization (NEDO), alongside matching grant mechanisms administered through AMED.
For later-stage companies, however, Japan has few dedicated neurotechnology funds. Venture capital reaches the sector through three more indirect channels.
The first is university-linked VC. University of Tokyo Edge Capital Partners (UTEC) closed its sixth fund at $326 million in July 2025, across more than 150 portfolio companies. Kyoto University Innovation Capital and Osaka University Venture Capital play similar regional roles, supporting the academic spinouts from which many Japanese neurotechnology companies emerge.
The second is the biotech and medtech fund layer. During the last quarter of 2025, AN Venture Partners, Fast Track Initiative, and Olympus Corporation launched healthcare-focused funds closing at $200 million, $130 million, and $150 million, respectively. These funds cover the medical device and clinical-stage categories that companies like Ivec occupy.
The third channel is corporate venture capital. More than 400 Japanese corporations now actively invest in startups, roughly double the 2018 figure. For neurotechnology, strategic investors from electronics, pharma, and trading houses can help fill gaps left by independent venture funds. Despite this broader expansion, several investors and founders argue that neurotechnology hardware remains structurally underfunded.
According to Sam Hosovsky, founder of uCat and an Osaka-based neurotechnology investor, public investment in next-generation neural interface technologies remains modest relative to international competitors. He estimates that across Japan’s three principal agencies supporting advanced neurotechnology research, JST, NEDO, and ATLA, less than $250 million has been allocated to novel neural interface development this decade. By comparison, he argues, U.S. public investment in neurotechnology hardware is roughly twenty times larger.
Hosovsky also points to international integration as a second challenge. Even as overseas interest in Japan’s neurotechnology sector grows, foreign collaboration and technology transfer can still face institutional and cultural resistance. Conditions vary across organizations, but researchers and investors frequently describe a cautious approach toward external partnerships, which can slow the entry of international actors into the ecosystem.
Japan’s startup support infrastructure has matured alongside these funding channels. SusHi Tech Tokyo, hosted annually by the Tokyo Metropolitan Government, brought together approximately 770 startups and an estimated 60,000 participants in April 2026, positioning itself as one of Asia’s largest startup conferences. Its sectoral focus spans AI, robotics, climate, and mobility, and it increasingly serves as an entry point for foreign investors evaluating the Japanese market.
More sector-specific platforms have also emerged. LINK-J’s UNIKORN program and the LINK-BioBAY Tokyo incubation cluster provide dedicated infrastructure for life science and neurotechnology ventures. The Hacosco-led BrainTech Consortium remains the country’s only neurotechnology-specific community body, with more than 2,700 members supporting coordination across researchers, startups, and industry actors.
Japan’s public programs generate strong foundational neuroscience and prototype systems. But the path toward scalable medical neurotechnology is less clearly defined. This gap is especially visible in implantable and invasive BCI systems, where clinical validation and regulatory approval are closely linked.
Stakeholders working on implantable technologies argue that established evaluation and approval pathways through the Pharmaceuticals and Medical Devices Agency (PMDA) remain comparatively underdeveloped for Class III medical devices, especially neural implants. Some Japanese startups pursuing invasive neurotechnology have therefore prioritized clinical development and regulatory engagement abroad before seeking domestic approval. For companies operating on startup timelines, this can extend business development cycles and make early commercialization more difficult.
At the manufacturing stage, Japan retains a significant advantage. The country has one of the world’s most mature original equipment manufacturer (OEM) ecosystems, with access to specialized suppliers, precision manufacturing, and established industrial infrastructure. Investors note that companies able to navigate the early funding stages can often scale production more efficiently than counterparts in markets where manufacturing capacity must be outsourced.
Japan has also shown that regulation can move quickly when frameworks are adapted to emerging technologies. In March 2026, Sumitomo Pharma’s AMCHEPRY, an iPSC-derived therapy for Parkinson’s disease developed at Kyoto University, received time-limited approval from Japan’s Ministry of Health, Labour and Welfare. The approval is regarded as the world’s first authorization of an iPSC therapeutic product. Under Japan’s regenerative medicine framework, products may receive conditional approval based on early evidence of safety and probable efficacy, while additional post-market data are collected within a defined period.
Researchers and investors often cite the case as evidence that Japan can move quickly when regulatory structures are built around emerging scientific fields. As Hosovsky argues, the country’s position varies significantly by domain. In his view, “In certain neurotech domains, Japan is and will remain a leader.”
Japan’s scientific and engineering base is strong, but the route to globally competitive neurotechnology companies remains fragmented across funding, regulation, and commercialization.
Japan is also active in the international policy conversation around neurotechnology. The OECD’s 2025 Neurotechnology Toolkit, which builds on its Recommendation on Responsible Innovation in Neurotechnology, cites Japan’s consent frameworks for neurological data collection as an illustrative example. Ryota Kanai of Araya serves as a vice-chair of UNESCO’s expert group drafting the Recommendation on the Ethics of Neurotechnology.
Japan’s most visible policy effort is the Trusted Neurotechnology Initiative, launched in late March 2026 as a public, interdisciplinary collaboration focused on the responsible development and use of neurotechnology. The initiative connects researchers and stakeholders and provides a Neurotech Guidebook developed inside the Moonshot Program since 2021.
This combination of public research funding and international ethics engagement suggests a deliberate effort to shape global norms while producing practical guidance that companies can use today.
“We expect continuous revision of the Guidebook and Evidence Book to not only lead to the creation of many new technologies, but also yield economic benefits through industrialization.” - Ryota Kanai
Japan’s neurotechnology ecosystem is distinct from its peers. Its institutional layer and governance focus give the commercial layer a degree of technical credibility and international visibility despite its smaller size. The strategy reflects a broader belief that public trust may become a competitive advantage as neurotechnology moves toward adoption, especially for jurisdictions that can turn responsible innovation principles into operational policy.
.svg)